December 2, 2019
CryoLife’s E-nside Thoracoabdominal Stent Graft Approved in Europe
December 2, 2019—CryoLife, Inc. announced that it has received European CE Mark approval for its E-nside thoracoabdominal multibranch stent graft system for the endovascular treatment of thoracoabdominal aortic aneurysms.
According to the company, the E-nside thoracoabdominal multibranch stent graft system features precannulated inner branches that are designed to reduce the overall procedure time and patient exposure to radiation.
The E-nside device was developed by Jotec GmbH, a German-based developer of technologically differentiated endovascular stent grafts and cardiac and vascular surgical grafts focused on aortic repair. CryoLife acquired Jotec in 2017. The E-nside stent graft system will be manufactured at the company’s facility in Hechingen, Germany.
The E-nside design is based on Jotec’s extensive experience with devices to treat thoracoabdominal disease. Jotec’s E-xtra Design Engineering program provides patient-specific solutions, providing synergy between E-nside and Jotec’s existing portfolio of thoracic and abdominal stent grafts.
Achmed Koshty, MD, from Diakonie Klinikum Jung-Stillen in Siegen, Germany, commented in the announcement, “E-nside, a new off-the-shelf multibranch endovascular stent graft system, addresses a significant unmet need in the endovascular treatment of the aorta. A life-saving device, E-nside provides a fast and secure option in the treatment of thoracoabdominal aneurysms. With the addition of E-nside, Jotec now offers a complete portfolio of the devices to treat aortic lesions from the aortic valve to the iliac arteries.”